1	The effectiveness of Evodia rutaecarpa hot compress on the recovery of gastrointestinal
2	function after laparoscopic surgery for colorectal cancer: A propensity score-matched
3	retrospective cohort study
4	
5	MiaoXin Huang ¹ , JunMiao Li ³ , Wei Huang ³ , YuLin Zhou ⁴ , Lei Cai ⁴ , Ming Liu ²
6	
7	¹ Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao SAR,
8	China
9	
10	² Peking University Health Science Center - Macao Polytechnic University Nursing
11	Academy, Macao Polytechnic University, Macao SAR, China
12	
13	³ The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,
14	Guangzhou, Guangdong, China
15	
16	⁴ The Third Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong,
17	China
18	
19	^{#a} Peking University Health Science Center - Macao Polytechnic University Nursing
20	Academy, Macao Polytechnic University, Macao SAR, China
21	

^{22 &}lt;sup>#b</sup>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Guangzhou, Guangdong Province, China

- 25 *Corresponding author
- 26 Email: karryliu@mpu.edu.mo
- 27 Email: cailei.0105@163.com
- 29 [¶]These authors contributed equally to this work.
- 30 [&]These authors also contributed equally to this work.

- -

- -+0

50 Abstract

51 Background

Although the use of hot compresses with the herbal medicine Evodia rutaecarpa (ER) as a complementary and alternative therapy to promote recovery of postoperative gastrointestinal function is gradually increasing in clinical practice, there is still a lack of relevant empirical studies. Particularly, the role of ER hot compress therapy on gastrointestinal recovery post-laparoscopic surgery for colorectal cancer has not been well investigated. The purpose of this study is to evaluate the efficacy and applicability of ER hot compress therapy for the recovery of postoperative gastrointestinal function.

59 Methods

This is a retrospective cohort study. Patients were divided into two cohorts, the ER group and the non-ER group. Propensity score matching(PSM) was introduced to limit confounding, and independent samples t-tests, non-parametric tests, or Chi-squared tests were used to compare these two cohorts.

64 **Results**

A total of 454 patients were included, with 267 (59%) receiving ER hot compress therapy and 187 (41%) not. Following 1:1 PSM, 320 patients were analyzed (160 in each group). Compared to the ER group, patients in the non-ER group had shorter times to return to a semi-liquid diet (p=0.035) and hospital stay (p=0.001), as well as lower hospital costs (p<0.001). Subgroup analyses revealed no statistically significant differences in the length of hospital stay, hospital costs, postoperative time to return to full-liquid diet, or time to return to semi-liquid diet among stage I and II tumor patients,

though means and standard deviations were generally lower in the ER group.
Complication incidence showed no significant difference between the two cohorts
before and after PSM.

75 Conclusions

The use of ER hot packs after laparoscopic surgery in patients with colorectal cancer has a non-significant effect on the recovery of the gastrointestinal function and, given the results of the study, it is likely that patients with early-stage tumors may benefit more. Therefore, healthcare providers need to consider the individualisation, practicality, and economics of treatment options.

Keywords: Colorectal cancer, Laparoscopy, Evodia rutaecarpa, Hot compress therapy,
Propensity score

83

84 Introduction

85 The World Health Organization (WHO) has released the latest estimates of the 86 global cancer burden, showing that colorectal cancer (CRC) is the third most common 87 cancer worldwide (over 1.9 million cases, 9.6%) and the second leading cause of cancer deaths (over 0.9 million cases, 9.3%)^[1]. In addition, the World Health Organization's 88 89 colorectal cancer epidemiological data for the whole of 2022 show that Asia ranks first 90 in terms of colorectal cancer incidence, mortality, and 5-year prevalence (colon, 91 rectum), followed by Europe with the second highest share^[2]. Studies have shown 92 that the incidence and mortality of CRC have decreased in some European, Oceanian 93 and North American countries in recent years ^[3-5], but data from the Chinese Cancer

94 Center in 2022 show that the incidence and mortality of CRC continue to increase ^{[3, 6-} 95 ^{7]}. Worryingly, the incidence of colorectal cancer is steadily increasing in China and 96 globally in people under the age of 50 ^[8-14]. Therefore, the prevention and treatment of 97 colorectal cancer are urgent, and various treatment regimes and technologies have 98 emerged. The surgical procedures have been moved from traditional open surgery to 99 laparoscopic surgery and robotic-assisted laparoscopic surgery.

100 However, postoperative colorectal cancer patients still face various challenges. 101 Among them, postoperative gastrointestinal dysfunction (POGD) is one of the common 102 complications of abdominal surgery, including laparoscopic colorectal cancer surgery 103 ^[15]. The most commonly occurring symptoms of POGD are nausea, vomiting, abdominal distention, postoperative intestinal ileus (POI), gastrointestinal bleeding, 104 105 and possibly progressive multi-organ failure^[5]. Therefore, a variety of complementary 106 and alternative therapies have been used to help restore gastrointestinal function after 107 surgery, particularly a range of herbal medicines.

108 In the past few years, Evodia rutaecarpa (ER), also known as Wuzhuyu (a type of 109 herbal medicine), has received increasing attention from various health professionals in 110 mitigating discomfort and supporting recovery from POGD. ER was first described 111 more than 2000 years ago in the Shennong Ben Cao Jing (a Chinese book on agriculture 112 and medicinal plants)^[16]. Nowadays, herbal therapy has attracted worldwide 113 attention^[17]. As an herbal remedy with potential value for CRC patients, ER is worth 114 exploring in depth. In China, the use of ER hot compress therapy is becoming 115 increasingly popular.

5

116 Based on the literature review, a study by Li and his colleagues showed that the 117 evodiamine and the rutaecarpine derived from ER have high permeability and remarkable selective transdermal properties^[18]. Furthermore, Gu and his colleagues 118 119 stated that sesquiterpenoids have significant pharmacological activities and suggested that the volatile oil of Cornus officinale can pass through PTGS1, PTGS2 and IL-6^[19]. 120 121 Because of these properties, ER is mixed with coarse salt in equal proportions to make 122 an ER hot compress bag in clinical practice, heated in a microwave oven at medium 123 heat for 4 minutes, and then applied to the patient's navel or Shengue point.

In the implementation of complementary and alternative therapies, not only doctors and rehabilitation therapists, but also nurses play an essential role. Therefore, when implementing complementary and alternative therapies, nurses should proactively understand their efficacy and applicability, use scientific and effective nursing practice based on evidence-based nursing, and strive to be patient advocates.

129 Therefore, this retrospective cohort study focused on colorectal cancer patients 130 undergoing laparoscopy to investigate the effect of ER hot compress therapy on the 131 recovery of postoperative gastrointestinal function.

132

133 Materials and method

134 **Study design and data source**

This was a retrospective cohort study based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (See S1 File.)^[20-21]. The study was approved by the Ethics Committee of Macao Polytechnic University

138 (approval number: FCSD/MSN-0051/2023) and the Institutional Review Board of the 139 Second Affiliated Hospital of Guangzhou University of Chinese Medicine (approval 140 number: ZE2023-459-01), and individual written informed consent was not required. 141 The study was conducted in accordance with the principles of the Declaration of 142 Helsinki, and the investigators collected electronic medical records of colorectal cancer 143 patients who underwent laparoscopic surgery at the Second Affiliated Hospital of 144 Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of 145 Chinese Medicine) from December 1, 2016 to December 30, 2022, including patient 146 demographics, perioperative data, and other information. Throughout the study, patient 147 data were de-identified (recorded and stored in a coded form).

148 Study sample

149 All data was collected from December 21st, 2023 to February 10th, 2024. The 150 study population was selected based on the following inclusion criteria: 1) meet the 151 diagnostic criteria for CRC in the 2017 edition of the Chinese Standards for the 152 Diagnosis and Treatment of CRC and further confirmed by pathological biopsy^[22]; 2) 153 all participants underwent elective standard laparoscopic radical tumor curettage; 3) the age of patients was between 25 and 80 years; 4) participants signed informed consent 154 155 for surgery and use of complementary and alternative therapies (herbal ER hot iron 156 therapy).

157 The exclusion criteria for the study were: 1) a confirmed diagnosis of distant 158 metastasis of the tumor; 2) combination with other malignant tumors; 3) physical 159 disability that prevents cooperation with functional exercises; 4) mental illness or

160 cognitive impairment that makes communication with the participant difficult; 5) 161 pregnancy or breastfeeding; 6) patients undergoing abdominal surgery within 6 months 162 and having severe intestinal adhesions; 7) patients with unsatisfactory control of the 163 primary medical disease; 8) concurrent other serious organic diseases; 9) preoperative abdominal infection; 10) patients requiring postoperative blood transfusion; 11) 164 165 patients requiring open surgery or extended radical surgery; 12) undergoing combined 166 abdominal perineal radical rectal cancer surgery (Miles procedure); 13) patients 167 experiencing serious complications within 6 hours of surgery or requiring admission to 168 intensive care after surgery; 14) patients with allergy to herbal ER therapy.

169 Definition and measurement of exposure factors and outcome 170 indicators

Patients were divided into two groups according to the exposure factor (i.e.
whether they received ER hot compress treatment after laparoscopic surgery for CRC):
the ER group and the conventional treatment group (the non-ER group).

174 1) The non-ER group only received routine postoperative care, including
175 monitoring of vital signs, postoperative fluid restoration, care of drainage tubes and
176 monitoring of drainage fluids, pain relief, surgical wound care and daily care.

177 2) The ER group received ER hot compress therapy and routine postoperative care.

178 250 grams of ER (from Guangdong Kangmei Pharmaceutical Co., Ltd.) and 250 grams

179 of coarse salt (Guangzhou Salt Industry Co., Ltd.) were placed in a cotton bag of 18

180 cm x23 cm and heated in a microwave oven at medium heat for 2 to 3 minutes. The

181 temperature of the ER hot pack was about 60 - 70 $^{\circ}$ C, and tolerable to the patient.

182 Nurses massage the ER hot pack in a clockwise direction with the Shengue point (navel) 183 as the centre for 20 circles, avoiding the surgical incision. The ER hot compress 184 treatment is usually started 24 hours after surgery, twice a day for 20 minutes each time. 185 3) Postoperative gastrointestinal outcomes and their measurements: time of first 186 postoperative flatus, time of first postoperative defecation, and time of recovery of 187 postoperative bowel sounds (the actual measurement of the above three items is 188 recorded from the end of the operation to the time when the doctor asks the patient 189 about the event, and it is not possible to calculate the exact time when the patient has 190 the above events), time of full-liquid diet and time of semi-liquid diet (the actual 191 measurement time is from the end of the operation to the time when the doctor gives 192 the order, i.e. the time when the patient starts the full-liquid diet) and the incidence of 193 postoperative gastrointestinal complications (including postoperative nausea and 194 vomiting, abdominal pain and bloating, anastomotic fistula, and bowel paralysis and 195 obstruction).

196 **Covariates**

197 The selection of covariates consists of three steps in this study. First, possible 198 covariates were selected based on the investigator's clinical experience and literature 199 review, including surgical site, tumor stage, history of chronic gastrointestinal disease, 200 intestinal stoma, gender, chronic lung disease, anaemia, hypoproteinaemia, history of 201 abdominal surgery, diabetes mellitus, hypertension, hyperlipidaemia, history of heart 202 disease, history of smoking, history of alcohol consumption, age, BMI, intraoperative 203 bleeding, and operative time. Second, the raw data were statistically analysed to screen for possible confounders based on the grouping variable (whether ER hot compress
therapy was used or not). Third, different caliper values were adjusted in the R language
software to analyse which covariates were likely to have an effect on the study results.
The main covariates examined were: 1) continuous variables: age and intraoperative
bleeding; 2) categorical variables: hyperlipidaemia and tumor stage.

209 Handling of missing data

Firstly, the type of data missing from the Electronic Medical Record System(EMR) information was analysed, such as the patient's basic information, BMI, and the time of the patient's first post-operative bowel movement;

Secondly, the analysis concluded that the reason for the missing data collected in this study was Missing Completely at Random (MCAR), due to human factors that were not recorded, omitted, or lost, and did not affect the unbiased nature of the sample: 1) it was divided into the following cases, and if there were more, the researcher simply deleted them; 2) if there were fewer missing values, those missing values were filled by interpolation using the mean and the plurality of the missing values.

219 Statistical methods

R4.2.3 software and SPSS 27.0 were used for statistical analysis. Measures that conformed to normal distribution and homogeneity of variances were expressed as mean standard deviation (mean \pm SD) and independent t-test was used for comparison between two groups, while those that did not conform to normal distribution were expressed as median (interquartile range), i.e. M (Q1, Q3) and Mann-Whitney U-test was used for comparison between two groups. Count data were expressed as cases (%)

and comparisons between two groups were made using the Pearson chi-squared test or
Fisher's exact test. All statistical inferences were made using two-tailed tests with a
statistically significant test level of a=0.05 and 95% CI for parameter CI estimation.

229

Propensity score matching

To assess the impact of confounding bias due to non-randomisation in 230 231 observational studies, propensity score matching (PSM) was proposed in this study^{[23-} ^{24]}. Four variables, tumor stage, hyperlipidaemia, intraoperative bleeding and age, were 232 233 used as covariates, and the use of ER hot packs was used as a grouping variable(exposure factor). Propensity scores were calculated for each sample using 234 235 nearest neighbour 1:1 matching and a caliper value of 0.05. In addition, the investigators visually compared the distribution difference of the two data sets before 236 237 and after matching by plotting distribution plots, density plots, and empirical 238 cumulative distribution function (eCDF) plots, respectively.

239 Sensitivity analysis

First, the parameters of the sensitivity analysis were determined, and common parameters included caliper values and matching ratios^[25]. The researcher evaluates and compares the matching results under different caliper values (e.g. selecting different caliper values of 0.02, 0.03, 0.05, 0.1, and 0.2; as well as selecting different matching ratios (e.g. ratio=1 and ratio=2) and also compares the matching results under different matching variables).

246 Second, the robustness and sensitivity of the PSM results can be assessed by 247 comparing the sample sizes after matching under different parameter settings by statistically analysing the results, and by assessing the distribution of the scores after matching by plotting distribution plots and histograms. It is assumed that the variation of the matching results under different parameter settings and different matching variables is small, which indicates that the matching results are less sensitive to the choice of parameters and have better robustness and sensitivity.

Equilibrium test

254 Equilibrium tests are used to assess whether the baseline characteristics between 255 the two data groups (ER and non-ER groups) before and after PSM are effectively 256 balanced. Commonly used equilibrium tests include the Standardised Mean Difference 257 (SMD), the Chi-square test, and the t-test^[26-27]. The SMD was used in this study to assess the effect of adjustment. If the SMD value is small (less than 0.1), it means that 258 259 the matching effect is good, the confounding factors between the two groups have been 260 effectively controlled, and the research results are credible. In addition, SMD plots and 261 histograms were used to visually analyse the baseline distribution of data between the two groups before and after matching. 262

263 Subgroup analysis

To further explore the heterogeneity of the samples after PSM, to analyse the variability of different treatments, and to improve the accuracy and reliability of the results, the researchers performed subgroup analyses of the pooled data. Because tumor staging is usually clinically relevant to the patient's postoperative treatment plan. Therefore, according to the American Joint Committee on Cancer (AJCC) cancer

staging system^[28] and the diagnosis of clinicians, tumor staging was divided into
different subgroups for analysis.

271

272 **Results**

273 The process of study population selection

274

Fig. 1 Flowchart of sample selection

275 **Before PSM**

276 Before matching, there were 267 cases in the ER group and 187 cases in the non-ER group. Statistical analysis was performed on the final 454 patients enrolled 277 278 (statistical values represent T value, U value, and chi-square value, respectively). This 279 analysis indicated that, firstly, the p-values for age and hyperlipidemia were 0.015 and 280 0.008, respectively, indicating statistical significance and potential impact on the results. 281 Secondly, compared to the non-ER group, patients in the ER group had higher hospital costs (p < 0.001), longer hospital stays (p < 0.001), and longer time to resume a semi-282 283 liquid diet after surgery (p = 0.021). The remaining results showed no statistical 284 significance (see Table 1 and S.Table 1) and other additional information is provided 285 in S.Table 2.

286 Table T Baseline data before PSM	286	Table 1 Baseline data before PSM
--------------------------------------	-----	----------------------------------

	Total	ER group	Non-ER group		
Variables	(n = 454)	(n = 267)	(n = 187)	р	statistic

Surgical Site, n (%)

0.758 0.095

Variables	Total	ER group	Non-ER group	n	statistic
Vallables	(n = 454)	(n = 267)	(n = 187)	р	statistic
Colon =1	164 (36.1)	98 (36.7)	66 (35.3)		
Rectum = 2	290 (63.9)	169 (63.3)	121 (64.7)		
Tumor-staging,				0.250	4.104
n (%)				0.230	4.104
I = 1	48 (10.6)	28 (10.5)	20 (10.7)		
II = 2	83 (18.3)	41 (15.4)	42 (22.5)		
III = 3	85 (18.7)	54 (20.2)	31 (16.6)		
unspecified = 4	238 (52.4)	144 (53.9)	94 (50.3)		
HCGD, n (%)				0.697	0.152
NO = 0	170 (37.4)	98(36.7)	72 (38.5)		
YES = 1	284 (62.6)	169 (63.3)	115 (61.5)		
Intestinal stoma,				0.911	0.012
n (%)				0.911	0.012
NO = 0	307 (67.6)	180 (67.4)	127 (67.9)		
YES = 1	147 (32.4)	87 (32.6)	60 (32.1)		
Gender, n (%)				0.960	0.003
Male $= 1$	247 (54.4)	145 (54.3)	102 (54.5)		

	Total	ER group	Non-ER group		-4-4:-4:-
Variables	(n = 454)	(n = 267)	(n = 187)	р	statistic
Female = 2	207 (45.6)	122 (45.7)	85 (45.5)		
CLD, n (%)				0.947	0.004
NO = 0	297 (65.4)	175 (65.5)	122 (65.2)		
YES = 1	157 (34.6)	92 (34.5)	65 (34.8)		
Anemia, n (%)				0.861	0.031
NO = 0	390 (85.9)	230 (86.1)	160 (85.6)		
YES = 1	64 (14.1)	37 (13.9)	27 (14.4)		
Hypoproteinemia,				0.760	0.093
n (%)				0.700	0.093
NO = 0	422 (93.0)	249 (93.3)	173 (92.5)		
YES = 1	32 (7.0)	18 (6.7)	14 (7.5)		
HAS, n (%)				0.890	0.019
NO = 0	339 (74.7)	200 (74.9)	139 (74.3)		
YES = 1	115 (25.3)	67 (25.1)	48 (25.7)		
Diabetes, n (%)				0.793	0.069
NO = 0	391 (86.1)	229 (85.8)	162 (86.6)		
YES = 1	63 (13.9)	38 (14.2)	25 (13.4)		

	Total	ER group	Non-ER group		
Variables	(n = 454)	(n = 267)	(n = 187)	р	statistic
Hypertension, n (%)				0.983	0.000
NO = 0	328 (72.2)	193 (72.3)	135 (72.2)		
YES = 1	126 (27.8)	74 (27.7)	52 (27.8)		
Hyperlipidemia,					
n (%)				0.008	7.075
NO = 0	353 (77.8)	196 (73.4)	157 (84.0)		
YES = 1	101 (22.2)	71 (26.6)	30 (16.0)		
HHD, n (%)				0.257	1.284
NO = 0	302 (66.5)	172 (64.4)	130 (69.5)		
YES = 1	152 (33.5)	95 (35.6)	57 (30.5)		
Smoking History,					
n (%)				0.534	0.387
NO = 0	349 (76.9)	208 (77.9)	141 (75.4)		
YES = 1	105 (23.1)	59 (22.1)	46 (24.6)		
Drinking History,				0.720	0 121
n (%)				0.728	0.121
NO = 0	401 (88.3)	237 (88.8)	164 (87.7)		

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group $(n = 187)$	р	statistic
YES = 1	53 (11.7)	30 (11.2)	23 (12.3)		
Age,Mean±SD	60.31 ± 9.88	59.37 ±10.32	61.65 ± 9.09	0.015	2.433
BMI, Mean±SD	22.91 ± 2.99	22.84 ± 3.03	23.01 ± 2.93	0.568	0.572
Intraoperative					
Hemorrhage_ml,	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.841	24696
Median (Q1,Q3)					
Operative Time_h,	(,		3.92(3.33, 4.73)	0.491	24018
Median (Q1,Q3)		4.00(3.50, 4.67)			
Hospital	Hospital 73733.17 ±		71310.96 ±	<	
Costs_CNY,	10823.33	75429.63 ± 11426.93	9409.44	0.001	-4.198
Mean±SD					
Length of Hospital					
Stay_d,	15.5 (14, 18)	16 (14, 19)	15 (13, 17)	0.001	20514
Median (Q1,Q3)					
NEBS,	NEBS, 10 (0, 16)		0 (0, 0)	<	0
Median (Q1,Q3)	(*, **)	16 (12, 20)	~ (~, ~)	0.001	-
TFPE_d,	1.83 (1.61,	1.85 (1.64, 2.69)	1.80 (1.60, 2.68)	0.101	22706.5
Median (Q1,Q3)	2.68)	1.05 (1.07, 2.09)	1.00 (1.00, 2.00)	0.101	22100.3

¥7 · 11	Total	ER group	Non-ER group		
Variables	(n = 454)	(n = 267)	(n = 187)	р	statistic
TFPD_d,	4.59 (2.64,			0.545	0.410.1
Median (Q1,Q3)	5.74)	4.63 (2.69, 5.66)	4.52 (2.58, 5.83)	0.545	24131
TRNBSAS_d,	4.87 (4.61,	4 00 (4 70 ((0)		0.000	20700
Median (Q1,Q3)	6.58)	4.90 (4.72, 6.68)	4.81 (3.61, 5.93)	0.002	20789
TFFFAS_d,	4.22 + 2.10	4.44 ± 2.04	4.16 ± 2.35		1.256
Mean±SD	4.33 ± 2.18	4.44 ± 2.04	1.10 - 2.55	0.173	-1.356
TFSFAS_d,		7.02 + 2.01	(41 + 2 52	0.021	2 210
Mean±SD	6.77 ± 2.80	7.03 ± 2.91	6.41 ± 2.59	0.021	-2.318
Postoperative					
Complications,				0.856	0.033
n (%)					
NO = 0	404 (89.0)	237 (88.8)	167 (89.3)		
YES = 1	50 (11.0)	30 (11.2)	20 (10.7)		

Notes: HCGD: History of Chronic Gastrointestinal Disease, HAS: History of
Abdominal Surgery, HHD: History of Heart Disease, CLD: Chronic Lung Disease,
TFPE: Time For First Postoperative Exhaust, TFPD: Time For First Postoperative
Defecation, TRNBSAS: Time to resuming normal bowel sounds after surgery, TFFFAS:
Time For First Full-liquid Feeding After Surgery, TFSFAS: Time For First Semi-liquid
Feeding After Surgery.

293 After PSM

294 The data of 454 patients underwent propensity score matching (PSM) analysis 295 using the nearest neighbor method, with age, tumor stage, intraoperative hemorrhage, 296 and hyperlipidemia as matching variables. Age and hyperlipidemia were identified as potential confounding factors before matching, while tumor stage and intraoperative 297 298 hemorrhage became statistically significant after adjusting for a smaller caliper value 299 and were thus included as matching variables. The matching ratio was 1:1, with a 300 caliper set at 0.05, resulting in successful matching of 320 patients, including 160 in 301 the ER group and 160 in the non-ER group.

Before PSM, there were significant differences between the ER and non-ER groups in terms of age and hyperlipidemia (with p-values of 0.041 and 0.008, respectively), indicating potential confounding factors. However, after PSM, the differences between the ER and non-ER groups in all characteristics became nonsignificant (all P>0.05, as detailed in Table 2), indicating successful achievement of balanced comparability after PSM.

Additionally, the Jitter Plot (see Fig. 2) illustrated that, after matching, the distributions of matching variables between the ER and non-ER groups tended to be consistent, indicating a good matching effect. The Density Plot and Empirical Cumulative Distribution Function Plot (eCDF plot) (refer to S1 Fig. and S2 Fig.) demonstrated that the density curves or cumulative distribution curves of the two groups' data were close to each other after matching, further validating the effectiveness of the matching method.

315	As shown in Table 2, after PSM, there were statistically significant differences in
316	postoperative gastrointestinal function recovery indicators between the two groups of
317	patients. Compared to the ER group, the non-ER group had a shorter time to restore
318	bowel sounds postoperatively (p=0.002) and an earlier initiation of a semi-liquid diet
319	(p=0.022). Furthermore, compared to the ER group, the non-ER group had lower
320	hospital costs (p<0.001) and shorter length of stay (p=0.001) (See S1 Table. for
321	additional information).

Variables	Total	ER group	Non-ER group	n	statistic
variables	(n = 320)	(n = 160)	group	р	statistic
			(n = 160)		
Surgical Site, n (%)				0.818	0.053
Colon =1	122 (38.1)	62 (38.8)	60 (37.5)		
Rectum = 2	198 (61.9)	98 (61.3)	100 (62.5)		
Tumor staging, n (%)				1.127	0.771
I = 1	30 (9.4)	13 (8.1)	17 (10.6)		
II = 2	57 (17.8)	30 (18.8)	27 (16.9)		
III = 3	54 (16.9)	25 (15.6)	29 (18.1)		
unspecified = 4	179 (55.9)	92 (57.5)	87 (54.4)		
HCGD, n (%)				0.251	1.317

322 Table 2 Baseline data after PSM

Variables	Total	ER group	Non-ER group	р	statistic
	(n = 320)	(n = 160)	(n = 160)		
NO = 0	124 (38.8)	57 (35.6)	67 (41.9)		
YES = 1	196 (61.3)	103 (64.4)	93 (58.1)		
Intestinal Stoma,				0.545	0.366
n (%)				0.545	0.500
NO = 0	221 (69.1)	113 (70.6)	108 (67.5)		
YES = 1	99 (30.9)	47 (29.4)	52 (32.5)		
Gender, n (%)				0.575	0.314
Male $= 1$	171 (53.4)	88 (55.0)	83 (51.9)		
Female = 2	149 (46.6)	72 (45.0)	77 (48.1)		
CLD, n (%)				1.000	0
NO = 0	210 (65.6)	105 (65.6)	105 (65.6)		
YES = 1	110 (34.4)	55 (34.4)	55 (34.4)		
Anemia, n (%)				0.623	0.242
NO = 0	277 (86.6)	140 (87.5)	137 (85.6)		
YES = 1	43 (13.4)	20 (12.5)	23 (14.4)		
Hypoproteinemia,				1.000	0

21

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	р	statistic
n (%)					
NO = 0	302 (94.4)	151 (94.4)	151 (94.4)		
YES = 1	18 (5.6)	9 (5.6)	9 (5.6)		
HAS, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Diabetes, n (%)				0.741	0.110
NO = 0	278 (86.9)	140 (87.5)	138 (86.3)		
YES = 1	42 (13.1)	20 (12.5)	22 (13.8)		
Hypertension, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Hyperlipidemia,				1.000	0
n (%)				1.000	v
NO = 0	260 (81.25)	130 (81.25)	130 (81.25)		
YES = 1	60 (18.75)	30 (18.75)	30 (18.75)		

Variables HHD, n (%)	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p 0.228	statistic 1.455
NO = 0	220 (68.75)	105 (65.6)	115 (71.9)		
YES = 1	100 (31.25)	52 (34.4)	45 (28.1)		
Smoking History,				0.789	0.072
n (%)				0.789	0.072
NO = 0	248 (77.5)	125 (78.1)	123 (76.9)		
YES = 1	72 (22.5)	35 (21.9)	37 (23.1)		
Drinking History,				0.210	1 572
n (%)				0.210	1.572
NO = 0	285 (89.1)	146 (91.3)	139 (86.9)		
YES = 1	35 (10.9)	14 (8.8)	21 (13.1)		
Postoperative				1.000	0
Complications, n (%)				1.000	Ū
NO = 0	296 (92.5)	148 (92.5)	148 (92.5)		
YES = 1	24 (7.5)	12 (7.5)	12 (7.5)		
Age,Mean±SD	59.99 ± 9.09	59.64 ± 9.43	60.34 ± 8.76	0.488	0.694
BMI, Mean±SD	22.89 ± 2.98	22.70 ± 3.05	23.08 ± 2.90	0.259	1.132

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	р	statistic
Intraoperative Hemorrhage_ml, Median (Q1,Q3)	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.161	11669.5
Operative Time_h, Median (Q1,Q3)	3.91 (3.42, 4.62)	3.92(3.50, 4.65)	3.90 (3.30, 4.61)	0.507	12251.5
Hospital Costs_CNY, Mean±SD	72435.17 ± 10123.06	74856.62 ± 11208.38	70013.72 ± 8256.44	< 0.001	-4.400
Length of Hospital Stay_d, Mean±SD	15.74 ± 3.85	16.46 ± 4.048	15.01 ± 3.495	< 0.001	-3.429
NEBS, Median (Q1,Q3)	3 (0, 16)	16 (12, 19.75)	0 (0, 0)	< 0.001	0
TFPE_d, Median (Q1,Q3)	1.83 (1.60, 2.63)	1.86 (1.60, 2.65)	1.80 (1.60, 2.60)	0.195	11728.5
TFPD_d, Median (Q1,Q3)	4.59 (2.65, 5.73)	4.64 (2.78, 5.66)	4.57 (2.63, 5.82)	0.439	12159.5
TRNBSAS_d,	4.86 (4.57,	4.92 (4.67,	4.80 (3.55,	0.002	10219.5

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	р	statistic
Median (Q1,Q3)	6.36)	6.62)	5.88)		
TFFFAS_d,	4.15 + 2.05	4.22 + 1.00	2.08 + 2.10	0.120	1.500
Mean±SD	4.15 ± 2.05	4.33 ± 1.99	3.98 ± 2.10	0.129	-1.522
TFSFAS_d,	(51 + 2.49	(01 + 2.50	(20 + 2 25	0.020	2 1 9 5
Mean±SD	6.51 ± 2.48	6.81 ± 2.58	6.20 ± 2.35	0.030	-2.185

323

324

Fig. 2 Jitter plot of the ER group and non-ER group after PSM

325 **Results of sensitivity analysis**

326 The sensitivity analyses revealed that with increasing caliper values and different 327 matching ratio conditions, the sample sizes of the matched ER and non-ER groups 328 exhibited minimal variation. When the ratio was set to 1, as the caliper value increased from 0.02 to 0.2 (caliper values of 0.02, 0.03, 0.1, and 0.2), the sample sizes gradually 329 330 increased with minor fluctuations, and the cumulative change in the number of cases 331 did not exceed 10% of the total sample size. For instance, the number of matches for 332 the ER and non-ER groups were 139/139, 150/150, 169/169, and 177/177, respectively. 333 Furthermore, when the ratio was set to 2 and the caliper value was 0.05, there were 175 334 matches for the non-ER group and 160 matches for the ER group. After matching, all 335 covariate p-values were greater than 0.05, indicating consistent results for each match

336 (see S3 Fig. and S4 Fig.).

Hence, this study demonstrates strong robustness in reaching consistent conclusionsacross various matching conditions, thereby enhancing the reliability and validity of the

339 findings.

Results of the equilibrium test

341 The equilibrium and comparability of the two groups of data after PSM was assessed by the Standardised Mean Differences (SMD) before and after matching (see 342 343 Table 3 and Fig. 3). Before matching, the SMDs of tumor stage, age and hyperlipidaemia exceeded 0.1, indicating the presence of large confounding factors. In 344 345 contrast, after matching, the SMDs of potential confounders were all less than 0.1, indicating improved sample balance. In addition, the histogram (see Fig. 4) visualised 346 347 that the histograms of the ER and non-ER groups showed more similar distribution patterns and locations after matching, further indicating that the two groups were more 348 349 similarly distributed in terms of the characteristic variables and that the PSM was 350 successful in reducing the propensity bias to achieve a balanced result.

351 Table 3 SMD before and after PSM

Before P	After PSM	
Variables	Std. Mean Diff.	Std. Mean Diff.
Tumor staging 1	-0.0068	-0.0816
Tumor staging 2	-0.1970	0.0520
Tumor staging 3	0.0908	-0.0622
Tumor staging 4	0.0735	0.0627

	Hyperlipidemia 0	-0.2388	0.0000
	Hyperlipidemia 1	0.2388	0.0000
	Age	-0.2210	-0.0685
	Intraoperative	-0.1678	0.0137
	haemorrhage_ml		
352			
353	Fig. 3 SMD plot of ER g	group and non-ER group l	before and after PSM
354			
355	Fig. 4 hist graph of ER g	group and non-ER group l	before and after PSM
356			
357	Results of subgroup and	alysis	
358	This study categorized tumo	or staging into four subgro	oups and conducted separate
359	statistical analyses for the ER gro	oup and non-ER group.	
360	1) Tumor Stage I: Compared	d to the non-ER group, pa	tients in the ER group had a
361	slightly longer mean time to full-	-liquid diet postoperative	ly (ER: 3.79 ± 1.25 vs non-
362	ER: 3.66 ± 1.20; p=0.765), slightly	y longer mean time to sem	ii-liquid diet postoperatively
363	(ER: 6.87 ± 2.78 vs. non-ER: 5.7	0 ± 1.91; p=0.181), slight	ly longer hospital stay (ER:
364	16.23 ± 3.30 vs. non-ER: 15.18 ±	± 2.63; p=0.338), and slig	htly higher average hospital
365	costs (ER: 75132.22 ± 12657.10 v	vs. non-ER: 69890.67 ± 11	096.58; p=0.238). However,
366	these differences between the gro	oups were not statistically	significant (see Table 4-1).
367	Table 4-1 Results of statistical an	alysis of dependent varia	bles for tumor stage I

Variables	Total (n = 30)	ER group (n = 13)	Non-ER group (n = 17)	р	statistic
Hospital Costs_CNY,	72162.01 ±	75132.22 ±	$69890.67 \pm$	0.000	1 207
Mean±SD	11883.00	12657.10	11096.58	0.238	-1.207
Length of Hospital Stay_d, Mean±SD	15.63 ± 2.93	16.23 ± 3.30	15.18 ± 2.63	0.338	-0.976
TFFFAS_d, Mean±SD	3.72 ± 1.20	3.79 ± 1.25	3.66 ± 1.20	0.765	-0.302
TFSFAS_d, Mean±SD	6.21 ± 2.36	6.87 ± 2.78	5.70 ± 1.91	0.181	-1.373
Postoperative				1.00	Fisher's
Complications, n (%)				1.00	exact test
NO = 0	27 (90.0)	12 (92.3)	15 (88.2)		
YES = 1	3 (10.0)	1 (7.7)	2 (11.8)		

368	2) Tumor stage II: Except for hospital costs, patients in the ER group had a shorter
369	mean time to full-liquid diet after surgery (ER: 4.15 ± 1.05 vs non-ER: 5.05 ± 3.11 ;
370	p=0.161), a shorter average time to semi-liquid diet after surgery (ER: 6.40 ± 1.21 vs
371	non-ER: 7.35 \pm 3.51; p=0.191), and a shorter average hospital costs (ER: 75576.01 \pm
372	10654.74 vs non-ER: 73310.87 \pm 7431.45; p=0.361), and shorter average hospital stay
373	(ER: 16.47 ± 2.69 vs. non-ER: 16.78 ± 4.68 ; p= 0.756) compared to the non-ER group,

although these differences were not statistically significant between groups (see Table

375 4-2).

Table 4-2 Results of statistical analysis of dependent variables for tumor stage II

Variables	Total (n = 57)	ER group (n = 30)	Non-ER group (n = 27)	р	statistic
Hospital Costs_CNY, Mean±SD	74503.05 ± 9259.14	75576.01 ± 10654.74	73310.87 ± 7431.45	0.361	-0.921
Length of Hospital Stay_d, Mean±SD	16.61 ± 3.73	16.47 ± 2.69	16.78 ± 4.68	0.756	0.312
TFFFAS_d, Mean±SD	4.57 ± 2.30	4.15 ± 1.05	5.05 ± 3.11	0.161	1.437
TFSFAS_d, Mean±SD	6.85 ± 2.59	6.40 ± 1.21	7.35 ± 3.51	0.191	1.335
Postoperative Complications, n (%)				1.000	Fisher's exact test
NO = 0	53 (93.0)	28 (93.3)	25 (92.6)		
YES = 1	4 (7.0)	2 (6.7)	2 (7.4)		

377	3) Tumor stage III and unspecified stage: According to Table 4-3, compared with
378	the ER group, the non-ER group had a significantly shorter postoperative time to semi-
379	liquid diet (ER: 8.35 ± 4.19 vs. non-ER: 6.45 ± 2.33), with a statistically significant
380	difference between the two groups (p=0.041); as shown in Table 4-4, compared with
381	the ER group, the non-ER group not only had a significantly shorter postoperative time
382	to semi-liquid diet (ER: 6.51 ± 2.18 vs. non-ER: 5.87 ± 1.85 ; p=0.034), but also had
383	significantly lower hospital costs (ER: 75510.44 \pm 11584.95 vs. non-ER: 69478.08 \pm
384	7643.31; p<0.001) and shorter hospital stays (ER: 16.29 \pm 3.957 vs. non-ER: 14.47 \pm
385	3.154; p<0.001), with significant statistical differences between the two groups.

386 Table 4-3 Results of statistical analysis of dependent variables for tumor stage III

	T- 4-1		Non-ER		
Variables	Total	ER group	group	р	statistic
	(n = 54)	(n = 25)	(n = 29)		
Hospital Costs_CNY,	69929.01 ±	71443.97±	68623.01 ±	0.257	1.146
Mean±SD	9049.86	9574.28	8522.77	0.257	-1.146
Length of Hospital		17.20 ±			
Stay_d, Mean \pm SD	15.96 ± 4.74	5.86	14.90 ± 3.26	0.075	-1.818
TFFFAS_d,					
Mean±SD	4.52 ± 2.20	5.10 ± 2.52	4.01 ± 1.79	0.069	-1.855
TFSFAS_d,					
Mean±SD	7.33 ± 3.43	8.35 ± 4.19	6.45 ± 2.33	0.041	-2.096

-

Variables	Total (n = 54)	ER group $(n = 25)$	Non-ER group (n = 29)	р	statistic
Postoperative				1 000	Fisher's exact
Complications, n (%)				1.000	test
NO = 0	49 (90.7)	23 (92.0)	26 (89.7)		
YES = 1	5 (9.3)	2 (8.0)	3 (10.3)		

387 Table 4-4 Results of statistical analysis of the dependent variable for tumor stage as

388 unspecified stage

	Total	ER group	Non-ER		
Variables	(n = 179)	(n = 92)	group	р	statistic
	(11 – 179)	(II – 92)	(n = 87)		
Hospital	72578.51±	75510.44 ±	69478.08 ±		
Costs_CNY,				< 0.001	-4.133
Mean±SD	10294.67	11584.95	7643.31		
Length of Hospital					
Stay_d,	15.41 ± 3.694	16.29 ±	14.47± 3.154	< 0.001	-3.416
Mean±SD		3.957			
TFFFAS_d,					
Mean±SD	3.98 ± 2.01	4.25 ± 2.11	3.69 ± 1.86	0.066	-1.853
TFSFAS_d,				/	
Mean±SD	6.20 ± 2.04	6.51 ± 2.18	5.87 ± 1.85	0.034	-2.131

Variables	Total (n = 179)	ER group (n = 92)	Non-ER group (n = 87)	р	statistic
Postoperative					Fisher's exact
Complications,				0.768	test
n (%)					lest
NO = 0	167 (93.3)	85 (92.4)	82 (94.3)		
YES = 1	12 (6.7)	7 (7.6)	5 (5.7)		

389

390 **Discussion**

391 ER is characterised by its pungent nature and spicy, bitter taste with low toxicity. 392 From a traditional Chinese medicine review, it is associated with the liver, spleen, 393 stomach, and kidney meridians. Its effects include dispersing cold and relieving pain, 394 reducing rebellious qi and stopping vomiting, and aiding yang tonification and stopping 395 diarrhoea^[29]. The "Shennong Bencao Jing" also describes ER as a mildly warm herb, mainly used for warming the middle, dispelling cold, removing dampness and blood 396 397 stasis, expelling wind evil and opening the body channels, and classifies it as a mediumgrade herb^[16]. 398

The Shen Que acupoint of the Ren meridian is located at the navel. The Ren meridian, one of the eight extraordinary meridians, intersects with the twelve ordinary meridians and serves as the hub of the meridian system, connecting hundreds of vessels and penetrating the five zang organs and six fu organs^[30-31]. Applying medicine to the

403 navel can promote circulation in the meridians, harmonise abdominal qi and relieve404 abdominal bloating and discomfort^[31].

405 Modern research has found that during embryonic development, the navel is the 406 final site of closure of the abdominal wall, lacking subcutaneous fat but containing 407 abundant blood vessels, lymphatic vessels and nerves, making it highly permeable^{[32-} 408 ^{34]}. Therefore, drug molecules can easily penetrate the epidermal keratin layer of the 409 umbilicus, rapidly infiltrate the intercellular space and exert their effects. In clinical 410 practice, the commonly used ER hot compress therapy uses local heat to facilitate the 411 penetration of drugs such as evodiamine and rutaecarpine from the ER into the abdomen 412 (around the navel) to accelerate the recovery of post-operative gastrointestinal 413 function^[35-36].

414 This retrospective cohort study aimed to investigate the effects of using ER hot 415 compress therapy on the recovery of gastrointestinal (GI) function in patients 416 undergoing colorectal cancer surgery. Currently, most retrospective cohort studies tend 417 to directly analyse the raw data to verify the effectiveness of ER hot compress therapy. 418 However, due to limitations in study design, those studies suffer from recall bias and 419 multiple confounding factors that do not adequately account for the importance of ER 420 hot compress therapy in the recovery of postoperative gastrointestinal function. To 421 reduce these confounding factors, this study adopted the PSM method, which is 422 commonly used in clinical practice, and investigated the factors that influence the 423 efficacy of ER hot compresses. At the same time, a subgroup analysis according to 424 tumor stage was performed to gain insight into the use of the method in patients with

425 different stages of the disease.

426 The results of our study showed that when comparing patients in the ER and non-427 ER groups, the matched results showed that there was no significant difference between 428 the two groups in terms of indicators related to gastrointestinal function after 429 laparoscopic surgery (p-values were all greater than 0.05), which was similar to the 430 results of the studies by Chen^[37] and Jian^[38]. Interestingly, however, when analysing the tumor stage into subgroups according to the AJCC TNM system^[28], we found that 431 432 the mean postoperative recovery time on a full-liquid diet was shorter in the ER group 433 for patients with tumor stage II compared to the non-ER group (non-ER group: $5.05 \pm$ 434 3.11 vs. ER group: 4.15 ± 1.05), the mean recovery time on semi-liquid diet was also 435 shorter (non-ER group: 7.35 ± 3.51 vs. ER group: 6.40 ± 1.21), and the mean length of 436 hospital stay was also shorter (non-ER group: 16.78 ± 4.68 vs. ER group: 16.47 ± 2.69). Although not statistically significant, these findings imply that patients with different 437 438 tumor stages may differ in the therapeutic efficacy of ER hot compress therapy, 439 suggesting that postoperative patients with early-stage tumors may be a potential 440 population to benefit from ER hot compress therapy.

In addition, the combination of ER hot compress therapy with other complementary and alternative therapies has been widely used after a variety of abdominal surgeries^[39-43]. These therapies include pain management^[44], ultrasound electroconductive transdermal drug delivery techniques^[45], moxibustion^[46], auricular acupressure and electroacupuncture^[47-48]. The results of clinical studies have shown that ER hot compress therapy combined with other therapies can not only improve the

34

447 symptoms of urinary retention, nausea and vomiting, abdominal distension and 448 abdominal pain in postoperative patients, but also promote the recovery of 449 gastrointestinal function in postoperative patients. However, because more than two 450 alternative therapies were combined, it was not possible to determine exactly which 451 therapy had a significant effect. Furthermore, although previous studies have explored 452 the impact of different treatment options on patient recovery, few studies have analysed 453 the cost-effectiveness of patients receiving complementary and alternative therapies 454 from an economic perspective, especially when looking at hospital costs and treatment 455 outcomes.

456 Therefore, our study filled the gap in previous research by conducting an in-depth 457 analysis of the cost-effectiveness of patients receiving complementary and alternative 458 therapies from an economic perspective. With a focus on assessing the economic impact 459 of these therapies, particular attention was paid to hospital costs, the length of hospital 460 stay and treatment outcomes. Our results indicate that patients receiving ER hot 461 compress therapy showed an overall increasing trend in hospital costs. However, further 462 analysis showed that there were no significant differences in hospital costs and the length of hospital stay between the ER and non-ER groups in different tumor stage 463 464 subgroups (including tumor stages I and II as well as stage III), with p-values all greater 465 than 0.2. Additionally, the length of hospital stay was not statistically significant for 466 patients with tumor stage I or II (p > 0.1). This finding suggests that although receiving 467 ER hot compress therapy may slightly increase overall patient costs, there was no 468 apparent economic disadvantage within specific subgroups. Therefore, our study

highlights the considerations that healthcare practitioners need to address how to
effectively use treatment modalities and techniques to improve patient recovery rates
and reduce hospital length of stay without significantly increasing patient costs.

472 Limitations

The limitations of this study may include: (1) due to inherent methodological 473 474 limitations of retrospective study, the accuracy of recording time of first postoperative 475 flatus, first postoperative defecation and recovery of postoperative bowel sound was 476 limited, which may have led to bias in the assessment of recovery of postoperative 477 gastrointestinal function, potentially affecting the reliability of the study conclusions. 478 (2) there was no statistical analysis of the differences in surgical experience between 479 surgeons, nor was there a detailed investigation of potential confounding factors such 480 as age and gender. (3) some objective laboratory indicators to validate the efficacy of ER hot compress therapy were not included. (4) the frequency of use of ER hot 481 482 compress therapy by patients was not discussed and the effect of frequency of use on 483 efficacy remains unclear. In addition, there may have been variability in the 484 implementation of ER hot compress therapy. (5) patients were not followed up, which might limit understanding of post-discharge outcomes. (6) selection bias could not be 485 486 avoidedi.e. patients with more severe conditions are more likely to choose 487 complementary and alternative therapies such as ER hot compress therapy. This may 488 lead to selection bias and might affect the results of the trial.

489 Therefore, we recommend the following.

490 First, plarger sample sizes, multicentre controlled prospective cohort studies or

36

medRxiv preprint doi: https://doi.org/10.1101/2024.05.07.24306986; this version posted May 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

491 randomised controlled trials are recommended. Second, future clinical studies on ER 492 hot compress therapy should explicitly state that the treatment team's characteristics 493 and the experiences of the surgeon to better control for potential confounding factors. 494 Third, the objective experimental indicators should be selected and not limited to 495 comparing the recovery of gastrointestinal function during hospitalisation after surgery, 496 follow-up observations, such as rehospitalisation rates and outpatient follow-up, should 497 be included to complement the assessment of postoperative recovery of gastrointestinal 498 function. Fourth, future studies should provide a more detailed record of the frequency 499 of ER hot compress therapy usage and explore how usage frequency affects treatment 500 efficacy. If possible, the overall effects on the recovery of postoperative gastrointestinal 501 function of different groups should be compared by follow-up after discharge. Finally, 502 future studies can employ qualitative research methods, such as interviewing patients 503 about their experiences of postoperative use of ER hot compress therapy, to 504 comprehensively evaluate the clinical benefits of this complementary and alternative 505 therapy.

506

507 Conclusion

508 The overall comparison suggests that Evodia rutaecarpa (ER) hot compress 509 therapy may not significantly promote recovery of gastrointestinal function, however, 510 patients with early-stage colorectal cancer may be a potential beneficiary group. 511 Therefore, healthcare providers should consider treatment diversity and patient 512 characteristics when formulating personalised treatment plans. By developing

- 513 treatment regimes based on scientific evidence and individual patient needs, healthcare
- 514 professionals can optimise treatment outcomes and effectively meet patient needs.

515

516 Acknowledgments

517 We would like to thank Mr. XiaoFeng Chen for his technical support and guidance.

518

519 Supporting information

- 520 S1 File. The Strengthening the Reporting of Observational Studies in Epidemiology
- 521 (STROBE) guidelines.
- 522 S1 Fig. The density plot of the ER group and non-ER group before and after PSM.
- 523 S2 Fig. The eCDF plot of the ER group and non-ER group before and after PSM.
- 524 S3 Fig. Differences in standard deviation plots of the ER group and non-ER group
- 525 before and after PSM under different caliper values.
- 526 S4 Fig. Histograms of the ER group and non-ER group before and after PSM at
- 527 different caliper values.
- 528 S1 Table. The 95% confidence intervals for continuous variables before and after PSM.
- 529 S2 Table. Types of postoperative complications.
- 530

531 **Reference**

532

[1]World Health Organization (WHO). Global cancer burden growing, amidst mounting need for services. [Accessed on 01 February 2024]. Available online:

https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing-amidst-mounting-need-for-services

- [2]World Health Organization. The Global Cancer Observatory: 2022 [Internet]. World Health Organization; 2024 Feb 8. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-factsheet.pdf
- [3]Garg R, Sayre EC, Pataky R, McTaggart-Cowan H, Peacock S, Loree JM, McKenzie M, Brown CJ, Yeung SST, De Vera MA. Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study. Cancer Epidemiol Biomarkers Prev. 2024 Jan 9;33(1):72-79. doi: 10.1158/1055-9965.EPI-23-0498. PMID: 37878338; PMCID: PMC10774739.
- [4]Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China.
 Lancet Gastroenterol Hepatol. 2022 Aug;7(8):700. doi: 10.1016/S2468-1253(22)00156-X. PMID: 35809603.
- [5]Li S, Liu KX, Deng XM, Fang XM, Xia ZY, Wang YL, Yu JB, Li JB, Shang Y, Zhou J. Expert consensus on prevention and treatment of postoperative gastrointestinal dysfunction. *Journal of International Anesthesiology and Resuscitation*. 2021;42(11):1133-1142. DOI:10.3760/cma.j.cn321761-20210811-10003.
- [6]Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond). 2023 Jan;43(1):75-86. doi: 10.1002/cac2.12393. Epub 2022 Nov 17. PMID: 36397729; PMCID:

medRxiv preprint doi: https://doi.org/10.1101/2024.05.07.24306986; this version posted May 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

PMC9859730.

- [7]Wang Z, Dan W, Zhang N, Fang J, Yang Y. Colorectal cancer and gut microbiota studies in China. Gut Microbes. 2023 Jan-Dec;15(1):2236364. doi: 10.1080/19490976.2023.2236364. PMID: 37482657; PMCID: PMC10364665.
- [8]Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu XC, Karlitz JJ. Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age. JAMA Netw Open. 2020 Jan 3;3(1):e1920407. doi: 10.1001/jamanetworkopen.2019.20407. Erratum in: JAMA Netw Open. 2020 Feb 5;3(2):e201038. PMID: 32003823; PMCID: PMC7042874.
- [9]GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):627-647. doi: 10.1016/S2468-1253(22)00044-9. Epub 2022 Apr 7. Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. PMID: 35397795; PMCID: PMC9192760.
- [10]Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. Gastroenterology. 2021 Mar;160(4):1041-1049. doi: 10.1053/j.gastro.2020.12.068. Epub 2021 Jan 5. PMID: 33417940; PMCID: PMC8273929.
- [11]Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, Kuipers
 EJ. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023 Apr 27;9(1):21.
 doi: 10.1038/s41572-023-00432-7. PMID: 37105987; PMCID: PMC10589420.
- [12]Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics,2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi:

10.3322/caac.21772. Epub 2023 Mar 1. PMID: 36856579.

- [13]Half EE, Levi Z, Mannalithara A, Leshno M, Ben-Aharon I, Abu-Freha N, Silverman B, Ladabaum U. Colorectal cancer screening at age 45 years in Israel: Cost-effectiveness and global implications. Cancer. 2024 Mar 15;130(6):901-912. doi: 10.1002/cncr.35097. Epub 2024 Jan 5. PMID: 38180788.
- [14]Howren A, Sayre EC, Loree JM, Gill S, Brown CJ, Raval MJ, Farooq A, De Vera MA. Trends in the Incidence of Young-Onset Colorectal Cancer With a Focus on Years Approaching Screening Age: A Population-Based Longitudinal Study. J Natl Cancer Inst. 2021 Jul 1;113(7):863-868. doi: 10.1093/jnci/djaa220. PMID: 33492399; PMCID: PMC8246802.
- [15]Jiang T, Li J, Meng L, Wang J, Zhang H, Liu M. Effects of transcutaneous electrical acupoint stimulation on gastrointestinal dysfunction after gastrointestinal surgery: A meta-analysis. Complement Ther Med. 2023 May;73:102938. doi: 10.1016/j.ctim.2023.102938. Epub 2023 Feb 25. PMID: 36842636.
- [16]Li AY. Shennong's Classic of Materia Medica (Illustrated Edition). Beijing: Minzhu yu jianshe chubanshe; 2021: 207.
- [17]World Health Organization. WHO traditional medicine strategy: 2014-2023
 [Internet]. World Health Organization; 2013 May 15. Available from: https://www.who.int/publications/i/item/9789241506096
- [18]Li DT, Wu XZ, He JL, Tang HM, Zhang LJ, Qiu ZW. Transdermal Drug Release Characteristics of Wuzhuyu Alkaloids and Wuzhuyu Alkaloids Determined by in vivo Skin Microdialysis Technique and HPLC. Chin Pharm J. 2015;03:239-243.

[19]Gu Q, Wei XC, Liu L, Liang Y, Li J, Dong J, Cai XY, Gu W, Chen J.

Exploration of the Pharmacological Substance Basis and Potential Molecular Mechanism of External Application of Volatile Oil of Pungent and Hot Chinese Medicine Based on Network Pharmacology. Chin Tradit Herb Drugs. 2021;05:1383-1392.

- [20]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;
 STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007 Oct 16;4(10):e296. doi: 10.1371/journal.pmed.0040296. PMID: 17941714; PMCID: PMC2020495.
- [21]STROBE. STROBE Checklist: cohort studies [Internet]. [Accessed in 2024]. Available from: https://www.strobe-statement.org/checklists/
- [22]National Health Commission of the People's Republic of China; Chinese Society of Oncology. [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 edition)]. Zhonghua Wai Ke Za Zhi. 2023 Aug 1;61(8):617-644. Chinese. doi: 10.3760/cma.j.cn112139-20230603-00222. PMID: 37400205.
- [23]Duhamel A, Labreuche J, Gronnier C, Mariette C. Statistical Tools for Propensity Score Matching. Ann Surg. 2017;265(6):E79-E80. doi:10.1097/SLA.00000000001312
- [24]Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimuseluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213-1222. doi:10.1056/NEJMoa1412168
- [25]Gu HQ. Statistical approaches and figures for sensitivity analysis in clinical research: a systematic review. Chin J Evid-Based Cardiovasc Med. 2018. doi:

10.3969/j.issn.1674-4055.2018.10.04.

- [26]Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009 Nov-Dec;29(6):661-77. doi: 10.1177/0272989X09341755. Epub 2009 Aug 14. PMID: 19684288.
- [27]Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011
 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8.
 PMID: 21818162; PMCID: PMC3144483.
- [28]Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4. PMID: 20180029.
- [29]Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia [Internet]. 10th ed. Beijing: China Medical Science Press; 2020 [cited 2024 Mar 20].
- [30]Liang BX, Yuan TH, Yan C, Wang LJ, Xian SX. On the Traditional Chinese Medicine Connotation of Navel Therapy. Chin J Tradit Chin Med. 2018;10:4329-4332.
- [31]Liang C, Deng HY, Zheng LP, Liu D, Zhang YJ, Wu XF, Yuan JH. [Clinical observation of traditional Chinese medicine application on umbilical region for treating opioid-induced constipation]. Chin J Clin Physician. 2017;45(7):119-121.
- [32]Li YH, Tao J. The effect of abdominal acupoint application therapy on the recovery of gastrointestinal function in patients with acute intestinal obstruction.Modern Journal of Integrated Traditional Chinese and Western Medicine.

2020;(01):87-91.

- [33]Lv SW, Pan SW, Fu QF, Guo YY, Sun S, Li YJ. Development overview and prospects of navel drug delivery formulations. Chin J Tradit Chin Med. 2015;06:109-112. doi:10.19664/j.cnki.1002-2392.2015.06.037.
- [34]Feng L, Ding MH, Shen Q, Sun QH, Shi SL. Factors affecting the percutaneous permeability of rhein at the Shenque acupoint: a study on preliminary mechanisms. Chin J Tradit Chin Med. 2016;08:1546-1552.
- [35]Li X, Shen Y, Pan G, Peng H. Effects of moxibustion with Wuzhuyu on gastrointestinal motility and gastrointestinal hormone secretion in patients after abdominal surgery. J Anhui Univ Chin Med. 2024;02:28-31.
- [36]Wang S, Lei XJ, Zhu WF, Huang ZG. Study on in vitro percutaneous absorption of vinegar-modified Wu Zhu Yu powder. Chin J Exp Tradit Med Form. 2013;10:31-34.
- [37]Chen Z, Cao L, Wen Z, Cui N, Li N, Xie J, Tan Z, Luo Z, Wang S, Qin Y, Chen X, Xu Z, Ou A, Shang W, Jiang Z, Chen Q. Study of Evodia hot compress plus electro-acupuncture in patients who have undergone abdominal surgery. Int J Clin Exp Med. 2015 Sep 15;8(9):16167-74. PMID: 26629130; PMCID: PMC4659019.
- [38]Jian L. Application of Traditional Chinese Medicine External Treatment in the Combination of Laparoscopic and Open Surgery for Rapid Recovery Surgery in Colorectal Cancer [master's thesis]. Guangzhou University of Chinese Medicine; 2010. Available from: https://kns.cnki.net/kcms2/article/abstract?v=eoCTaIZmBOOIo2BJaiSkM9x5 UbJWb3bIFw3CQ_YnXnl9HVFsAG_0tChqZ1cSOuYxqOmNeUDGmxlpvo1 Iey1-JOTRJHj5PUwJKC0wu97m52osQoRbfKb38C-

SR2MWo6lnqxtUSxU1BV4vsVU0FUmkyA==uniplatform=NZKPTlanguage =CHS.

- [39]Wu JP, Ouyang FJ, Li ZS, Wu YR. Observation on the Effect of Enhanced Recovery Surgical Nursing Combined with Wuzhuyu Hot Compress External Application on Patients after Laparoscopic Appendectomy. J Baotou Med Coll. 2020;11:86-89. doi:10.16833/j.cnki.jbmc.2020.11.024
- [40]Yu J, Zhang ZJ, Liu YR. Effects of external application of Wuzhuyu on gastrointestinal function and inflammatory markers in patients after colon cancer surgery. J External Ther Tradit Chin Med. 2021;06:7-8.
- [41]Zhu CH, Zhou ZZ. Effects of wuzhuyu fumigation combined with acupoint massage on postoperative abdominal distention and pain in patients with uterine fibroids undergoing laparoscopic surgery. J Jiangxi Univ Tradit Chin Med. 2022;05:56-59.
- [42]Wen HJ, Wang JH, Zeng MF, Tan FN, Xie WJ. Effects of meridian acupoint massage combined with Wuzhuyu coarse salt hot compress on gastrointestinal function recovery after rectal cancer surgery. Syst Med. 2023;20:124-127. doi:10.19368/j.cnki.2096-1782.2023.20.124.
- [43]Li L, Wei RL, Cao H, Wei LJ, Shen JW, Sun M, Wang GL. Effects of Wuzhuyu coarse salt hot compress on gastrointestinal function recovery in patients with colorectal cancer after surgery under the guidance of enhanced recovery surgical concept. Colorectal Anal Surg. 2021;5:508-510+514. doi:10.19668/j.cnki.issn1674-0491.2021.05.025.
- [44]Zhang LQ, Zhang QS, Hu Y. Application of Pain Care Combined with Wuzhuyu Hot Compress in Postoperative Patients of Urological Laparoscopy. Gen Nurs. 2015;24:2374-2376.

- [45]Li LQ, Luo JY, Zhou XD, Chen PQ, Hu HQ, Liu Y, Zhang LJ. Efficacy analysis of hot compress with Evodia rutaecarpa combined with ultrasonic conductivity meter in promoting gastrointestinal function recovery in patients undergoing gastrointestinal surgery. Med Pharm High Vocat Educ Mod Nurs. 2023;(06):500-502+507.
- [46]Xu LG. Perioperative Application of Moxibustion and Hot Compress in Laparoscopic Cholecystectomy. J Pract Tradit Chin Med. 2013;03:150-153.
- [47]Chen Y, Gan Q, Zhang YH, Tang LP, Xiong ZF. Application effect of wuzhuyu hot compress combined with ear acupoint pressing beans in patients after laparoscopic surgery in urology department. J Pract Clin Med. 2023;06:74-77+91. doi:10.13764/j.cnki.lcsy.2023.06.019.
- [48]Qu HH, Qu XL, Li M. Study on the efficacy of Wuzhuyu abdominal hot compress combined with acupuncture at Zusanli point in promoting rapid recovery after laparoscopic surgery for colorectal cancer. Chin J Med Pharm. 2021;06:175-177+181.


533

534


535


536

537



Distribution of Propensity Scores





Raw Treated

Matched Treated

